Biotech

All Articles

A better check out Ferocious Biotech's Brutal 15

.Within this week's episode of "The Best Line," our experts are actually diving right into Brutal Bi...

Lilly deals with stage 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's event celebrating the approval of Alzheimer's ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of considerable management hirings, shooting...

Lykos are going to inquire FDA to reassess its decision adhering to denial of MDMA treatment for post-traumatic stress disorder

.Adhering to an unsatisfactory revealing for Lykos Therapies' MDMA prospect for post-traumatic stres...

AN 2 one-halfs census, quits stage 3 trial after records let down

.AN2 Therapies is actually rethinking its service in action to lackluster midphase information, swea...

Merck spends $700M for bispecific, spying autoimmune opening and odds to test Amgen in cancer cells

.Merck &amp Co. is paying out $700 thousand ahead of time to test Amgen in a blood cancer market. Th...

Gilead pays out J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its liver illness drug seladelpar, the firm has act...

' All palms on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks may view the companies putting together tents at basecamp behin...

Entero laying off staff, vacating office and also stopping R&ampD

.Cushion Liquidators has switched Entero Rehabs white as a sheet. The creditor ordered Entero to rep...

Exelixis drops ADC after deciding it's no match for Tivdak

.Exelixis is surrendering on its cells aspect (TF)- targeting antibody-drug conjugate after ending t...